THERAPY DOSSIER · th-dc37d6537bbe

Delta-9-tetrahydrocannabinol

Drug · Cannabinoid CB1 receptor agonist (AGONIST)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Cannabinoid CB1 receptor agonist (AGONIST)
Target: CHEMBL218
Injury models: Other
Reported indication: Not recorded
First approval: 1985
Development stage: Not recorded
ChEMBL record: CHEMBL465 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Delta-9-tetrahydrocannabinol; THC; Marinol; Syndros
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02901275 ↗PHASE2completed

Trial title not recorded

Pain · Opioid Use

Enrolment: 29 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25425209 ↗2015Reported benefit

Delta(9) Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.

MouseOtherC3H/HeJFemale

Model: Dual intranasal and intraperitoneal Staphylococcal enterotoxin B administration causing inflammatory lung injury and toxic shock

Staphylococcal enterotoxin B exposure caused acute mortality whereas THC treatment led to 100% survival, and THC inhibited the individual microRNAs of the miR-17-92 cluster, reversing enterotoxin-driven suppression of regulatory T cells.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…